World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT01429909
Date of registration: 07/07/2011
Primary sponsor: University Hospital, Clermont-Ferrand
Public title: Optimization of fMRI for the Study of Basal Ganglia Activation in Parkinson's Disease
Scientific title: Optimization of fMRI for the Study of Basal Ganglia Activation in Parkinson's Disease: T2* Measurement in the Cortex and the Basal Ganglia
Date of first enrolment: February 2011
Target sample size: 80
Recruitment status: Recruiting
URL:  http://clinicaltrials.gov/show/NCT01429909
Study type:  Interventional
Study design:  Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic  
Countries of recruitment
France
Contacts
Name:   Patrick LACARIN
Address: 
Telephone: 04 73 75 11 95
Email: placarin@chu-clermontferrand.fr
Affiliation: 
Name:   Patrick LACARIN
Address: 
Telephone: 04 73 75 11 95
Email: placarin@chu-clermontferrand.fr
Affiliation: 
Name:   Miguel ULLA
Address: 
Telephone:
Email:
Affiliation:  University Hospital, Clermont-Ferrand
Key inclusion & exclusion criteria

Inclusion Criteria:

- For patients :

- Patients with idiopathic Parkinson's disease according to UKPDSBB criterias

- Men or women aged between 40 to 80 years

- not treated with deep brain stimulation

For healthy subjects

- Men or women aged between 40 to 80 years

Exclusion Criteria:

For patients

- Dementia (MMS<24)

- Contraindication to MRI.

- Under guardianship

- In excluding period for another study

For healthy subjects

- Antecedent of neurodegenerative diseases or psychiatric diseases

- Contraindication to MRI

- Under guardianship

- In excluding period for another study



Age minimum: 40 Years
Age maximum: 80 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Parkinson's Disease
Intervention(s)
Device: MAGNETOM Avanto (MRI device)
Primary Outcome(s)
The quantitative measurement of T2* in the cortex and basal ganglia using MRI, made à J0. [Time Frame: at day 1]
Secondary Outcome(s)
Secondary ID(s)
CHU-0097
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history